LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciaf074 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Nobumasa Okumura und 23 weiteren Autor:innen. Beteiligte Einrichtung: Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-Ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, Mpox, Monkeypox. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: FY2023 Health, Labour and Welfare Administration Promotion Survey Project Grant, Ministry of Health, Labour and Welfare.
Abstract (Originalsprache)
Background
This randomized controlled trial provided LC16m8 pre-exposure prophylaxis to high-risk individuals to assess its efficacy for mpox prevention, safety, and immunogenicity.
Methods
This multicenter, randomized, open-label trial enrolled men and women aged ≥18 years at high risk of mpox. Participants were randomly assigned 1:1 to early- or late-vaccination groups. The primary endpoint was vaccine efficacy (VE) against mpox. Secondary endpoints included VE against severe mpox, symptoms, “take” incidence, adverse events (AEs), and immunogenicity in participants with human immunodeficiency virus (HIV).
Results
In total, 570 and 565 participants were assigned to early- and late-vaccination groups, respectively, with 530 and 476 vaccinated. The median age was 41 years; 99.7% were male, 89.7% were Japanese, and 34.4% had HIV. No mpox cases occurred, precluding VE calculations. The take rates were 89.5% (with HIV) and 93.9% (without HIV). AEs occurred in 97.2% and 98.2% of participants with and without HIV, respectively. No fatal AEs were observed. Serious adverse events (SAEs) were observed in 2/352 (0.6%) and 3/654 (0.5%) of participants with and without HIV, respectively, of which 1 SAE causally related to vaccination occurred in a participant without HIV. Seroconversion rates for LC16m8 and MPXV were 96.2% and 69.2%, respectively, in participants with HIV, and 92.0% and 52.0%, respectively, in individuals without HIV.
Conclusions
LC16m8 efficacy in mpox remains inconclusive. However, in individuals with well-controlled HIV, it was immunogenic and raised no significant safety concerns, suggesting its suitability for targeted vaccination of at-risk groups. (Japan Registry of Clinical Trials number, jRCT1031230137)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-Ku, Tokyo, Japan.
- Center for Clinical Sciences, National Center for Global Health and Medicine, Shinjuku-Ku, Tokyo, Japan.
- Department of Respiratory Medicine, National Center for Global Health and Medicine, Shinjuku-Ku, Tokyo, Japan.
- Department of Infectious Diseases, Keio University School of Medicine, Shinjuku-Ku, Tokyo, Japan.
- Division of Clinical Research and Education, National Center for Global Health and Medicine, Shinjuku-Ku, Tokyo, Japan.
- AIDS Clinical Center, National Center for Global Health and Medicine, Shinjuku-Ku, Tokyo, Japan.
ORCID-Profile: Nobumasa Okumura, Hidetoshi Nomoto, Yosuke Shimizu, Daisuke Mizushima, Ei Kinai, Tadaki Suzuki, Norio Ohmagari, Mugen Ujiie
Förderung
- FY2023 Health, Labour and Welfare Administration Promotion Survey Project Grant
- Ministry of Health, Labour and Welfare
Zitieren
APA
Okumura, N., Morino, E., Nomoto, H., Yanagi, M., Takahashi, K., Iwasaki, H., Uemura, Y., Shimizu, Y., Mizushima, D., Fukushima, K., Kinai, E., Shiojiri, D., Itoda, I., Onoe, Y., Kobori, Y., Nakamura, F., Tokita, D., Sugiura, W., Ueno, S., …, & Ujiie, M. (2026). LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf074
Vancouver
Okumura N, Morino E, Nomoto H, Yanagi M, Takahashi K, Iwasaki H, et al. LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf074
BibTeX
@article{Okumura2026,
author = {Okumura, Nobumasa and Morino, Eriko and Nomoto, Hidetoshi and Yanagi, Mashiho and Takahashi, Kozue and Iwasaki, Haruka and Uemura, Yukari and Shimizu, Yosuke and Mizushima, Daisuke and Fukushima, Kazuaki and Kinai, Ei and Shiojiri, Daisuke and Itoda, Ichiro and Onoe, Yasuhiko and Kobori, Yoshitomo and Nakamura, Fukumi and Tokita, Daisuke and Sugiura, Wataru and Ueno, Shiori and Ainai, Akira and Mine, Sohtaro and Suzuki, Tadaki and Ohmagari, Norio and Ujiie, Mugen},
title = {LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciaf074}
}
EUVIMED